VCYT - Veracyte, Inc.
Connor Clark and Lunn Investment Management Ltd. bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 26,948 shares of the biotechnology company's stock, valued at approximately $1,583,000. Other hedge funds and other institutional investors have also recently
Bamco Inc. NY purchased a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 650,686 shares of the biotechnology company's stock, valued at approximately $38,215,000. Bamco Inc. NY owned approximately 0.81% of Veracyte at the
VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Bank of America Corp DE grew its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 14.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,448,897 shares of the biotechnology company's stock after buying an additional 185,929 shares during the period.
Veracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins. I think that bodes well for VCYT's potential as a long-term cash flow machine. Moreover, VCYT's Prosigna and TrueMRD add more long-term upside, which management hasn't yet included in its recent 2026 testing-revenue guidance.
Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement infrastructure. Q2 2026 results showed 15% revenue growth, 23% adjusted EBITDA growth, and 29.2% EBITDA margin, with robust cash generation and no funded debt. Prosigna and TrueMRD launches offer significant upside, as 2026 guidance excludes their contributions, while Decipher and Afirma drive core growth and margin expansion.
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
Veracyte (VCYT) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.44 per share a year ago.
Grew total revenue to $150.3 million and testing revenue to $145.7 million , representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences:
First Trust Advisors LP lifted its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 64.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,117,046 shares of the biotechnology company's stock after acquiring an additional 833,543 shares during the
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.
Fifth Third Bancorp boosted its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 10,285.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,549 shares of the biotechnology company's stock after purchasing an additional 52,043 shares during the period. Fifth Third
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
Amova Asset Management Americas Inc. lessened its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 16.9% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,045,047 shares of the biotechnology company's stock after selling 212,851 shares during the quarter. Amova
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.